Skip to main content.

Anne P. O'Dea, MD

Anne O'Dea portrait
Medical Director, Breast Cancer Survivorship, Medical Director, Breast Cancer Survivorship

Medical Director, Breast Cancer Clinical Research Program Services, Medical Director, Breast Cancer Clinical Research Program Services

aodea@kumc.edu

Professional Background

Dr. Anne O'Dea is certified by the American Board of Internal Medicine with subcertification in hematology and medical oncology. She completed a fellowship at the University of Kansas Medical Center. She earned her medical degree from the University of Kansas School of Medicine and completed her residency at the University of Kansas Medical Center.



Education and Training
  • BGS, Human Biology, University of Kansas
  • MD, Medicine, University of Kansas-Medical Center
  • Residency, Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
  • Post Doctoral Fellowship, Hematology and Oncology, University of Kansas School of Medicine, Kansas City, KS
  • Post Doctoral Fellowship, Breast Oncology, University of Kansas School of Medicine, Kansas City, KS
Licensure, Accreditations & Certifications
  • ABIM Certification in Hematology, American Board of Internal Medicine
  • ABIM Certification in Internal Medicine, American Board of Internal Medicine
  • ABIM Certification in Medical Oncology Recertified 04/2022, American Board of Internal Medicine
  • Kansas Medical License, Kansas Board of Healing Arts
Professional Affiliations
  • Southwest Oncology Group, Breast Cancer Survivorship and Prevention and Epidemiology Committee, Member, 2017 - Present
  • University of KS Cancer Center, Breast Disease Working Group, Member, 2017 - Present
  • Accreditation Council for Graduate Medical Education, Fellowship Milestones Committee, Member, 2016 - 2019
  • Southwest Oncology Group, Southwest Oncology Group, Member, 2015 - Present
  • American College of Surgeons, Commission on Cancer Committee, Member, 2014 - 2017
  • American Society of Clinical Oncology, Member, 2007 - Present

Current Research and Grants
  • Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ Breast Cancer, Phase III (S1501 Trial), NCI UGICA189974/SWOG (HSC #141492)
  • Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cylin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (MAINTAIN Study), Columbia University Medical Center. Clinical Trial, HSC #144455
  • Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT), National Cancer Institute/National Heart Lung Blood Institute - Clinical Trial HSC#144677
  • PROspective Evaluation of Germline Mutations, Cancer Outcomes and Tissue Biomarkers (P.R.O.G.E.C.T.), University of Kansas Medical Center (KU IRB #140761) Registry, HSC 12614
  • Task Evoked Pupillary Response (TEPR): Cognitive Effort for Breast Cancer Survivors, University of KS Cancer Center Internal Grant
  • KanSurvive: Testing Model for Improving Cancer Survivorship in Rural Practice, National Cancer Institute/R01 RFA-CA-18-026
  • Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients with ER+ HER2- Primary Breast Cancer (the "Study"), Sanofi - Clinical Trial HSC #145320
Publications
  • Griffiths, Jason., I, Chen, Jinfeng, Cosgrove, Patrick., A, O'Dea, Anne., P, Sharma, Priyanka, Ma, Cynthia, Trivedi, Meghna, Kalinsky, Kevin, Wisinski, Kari., B, O'Regan, Ruth, Makhoul, Issam, Spring, Laura., M, Bardia, Aditya, Adler, Frederick., R, Cohen, Adam., L, Chang, Jeffrey., T, Khan, Qamar., J, Bild, Andrea., H. 2021. Serial Single-Cell Genomics Reveals Convergent subclonal Evolution of Resistance as Patients with Early-Stage Breast Cancer Progress on Endocrine Plus CDK4/6 Therapy. Nature Cancer, 2 (6), 658-671. Article | -Serial | Single-Cell | Genomics | Reveals | Convergent | Subclonal | Evolutions... | Khan_s43018-021-00215-7_1624980171_1.pdf |
  • Sharma, Priyanka, Kimler, Bruce., F, O'Dea, Anne., P, Nye, Lauren., E, Wang, Yen, Yoder, Rachel, Staley, Joshua, Prochaska, Linda, Wagner, Jamie, Amin, Amanda, Larson, Kelsey, Balanoff, Christa, Elia, Manana, Crane, Gregory, Madhusudhana, Sheshadri, Hoffmann, Mark, Sheehan, Maureen, Rodriguez, Roberto, Finke, Karissa, Shah, Rajvi, Satelli, Deepti, Shrestha, Anuj, Beck, Larry, McKittrick, Richard, Pluenneke, Robert, Raja, Vinay, Venkatadri, Beeki, Corum, Larry, Heldstab, Jaimie, LaFever, Stephanie, Prager, Micki, Phadnis, Milind, Mudaranthakam, Dinesh., Pal, Jensen, Roy, Godwin, Andrew, Salgado, Roberto, Mehta, Kathan, Khan, Qamar. 2021. Randomized Phase II Trial of Anthracycline-Free and Anthracycline-Containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-Negative Breast Cancer (NeoSTOP). Clinical Cancer Research, 27 (4), 975-982. https://clincancerres.aacrjournals.org/content/27/4/975 |
  • Sharma, Priyanka, Abramson, Vandana, O'Dea, Anne, Nye, Lauren., E, Mayer, Ingrid, Pathak, Harsh, Hoffmann, Marc, Stecklein, Shane, Elia, Manana, Lewis, Sharon, Scott, Jecinda, De Jong, Jilliann, Wang, Yen, Yoder, Rachel, Schwensen, Kelsey, Finke, Karissa, Heldstab, Jaimie, LaFaver, Stephanie, Williamson, Ste, Phadnis, Milind, Reed, Gregory, Kimler, Bruce., F, Khan, Qamar., J, Andrew. 2021. Clinical and Biomarker Results from Phase I/II Study of P13K Inhibitor Alpellsib Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 27 (14), 3896-3904. https://clincancerres.aacrjournals.org/content/clincanres/early/2021/02/17/1078-0432.CCR-20-4879.full.pdf |
  • Larson, Kelsey., E, Wang, Yen., Y, Finke, Karissa, Yoder, Rachel, Schwensen, Kelsey, O'Dea, Anne., P, Khan, Qamar., J, Nye, Lauren., E, Heldstab, Jaimie, Godwin, Andrew., K, Kimler, Bruce., F, Sharma, Priyanka. 2020. Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer. Journal of Cancer Treatment and Research, 7, 81-86. https://www.researchgate.net/publication/338517006_Impact_of_Germline_BRCA_Mutation_Status_on_Survival_in_Women_with_Metastatic_Triple_Negative_Breast_Cancer
  • Sharma, Priyanka, Kimler, B., F, O'Dea, Anne., P, Nye, Lauren., E, Wang, Y., Y, Yoder, R, Prochaska, L., H, Wagner, J., L, Amin, A., L, Larson, K, Balanoff, C, Elia, M, Crane, G., J, Madhusudhana, S, Hoffmann, M., S, Sheehan, M, Rodriguez, R., R, Jensen, Roy., A, Godwin, Andrew., K, Khan, Qamar., J. 2019. Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in state I-III triple-negative breast cancer. Journal of Clinical Oncology, 37 (abstr 516 no. 15 suppl), 516-516. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.516
  • O'Dea, Anne, Khan, Meshaal, Haines, Haley., Isabela, Kimler, Bruce., F., Nye, Lauren., Elizabeth, Sharma, Priyanka, Khan, Qamar., J.. 2019. Fixed dose, dose-dense capecitabine in metastatic breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, 37 (15 )
  • Myers, J., S, Nesreen, A, Mitchell, M, Dai, J, He, J, Moon, S, O'Dea, A, Klemp, J, Kurylo, M, Akinwuntan, A, Devos, H. 2020. Pilot Feasibility Study Examining Pupillary Response During Driving Simulation as a Measure of Cognitive Load in Breast Cancer Survivors. Oncol Nurs Forum, 47 (2), 203-212. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057397/ |
  • Myers, Jamie., S., Kahya, Melike, Mitchell, Melissa, Dai, Junqiang, He, Jianghua, Moon, Sanghee, Hamilton, Kevin, Valla, Mary, O'Dea, Anne, Klemp, Jennifer, Kurylo, Monica, Akinwuntan, Abiodun, Devos, Hannes. 2019. Pupillary response: cognitive effort for breast cancer survivors. SUPPORTIVE CARE IN CANCER, 27 (3), 1121-1128. Pupillary | response: | cognitive | effort | for | breast | cancer | survivors | | | SpringerLink |
  • Kilgore, L., J, Korentager, S., S, Hangge, A., N, Amin, A., L, Balanoff, C., R, Larson, K., E, Mitchell, M., P, Chen, J., G, Burgen, E, Khan, Q., J, O'Dea, A., P, Nye, L, Sharma, P, Wagner, J., L. 2018. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions.. Annals of Surgical Oncology, 25 (10), 2948-2952. https://link.springer.com/article/10.1245/s10434-018-6601-8
  • O'Dea, Anne., P, Sharma, Priyanka. 2018. Management of Metastatic Triple-Negative Breast Cancer. Triple-Negative Breast Cancer (1), 95-116